BazEkon - Biblioteka Główna Uniwersytetu Ekonomicznego w Krakowie

BazEkon home page

Meny główne

Autor
Czech Marcin (IMS Health and Business School, Warsaw University of Technology), Jasiński Zbigniew (IMS Health), Krupa Dominika (IMS Health)
Tytuł
Real-life Treatment Patterns and Medication Costs in Patients with Hypertension Treated with Ramipril Monotherapy or Ramipril Loose and Fixed Combinations in Poland
Źródło
Journal of Health Policy and Outcomes Research, 2015, nr 2, s. 31-43, rys., tab., bibliogr. 16 poz.
Słowa kluczowe
Leki, Koszty, Leczenie, Choroby przewlekłe
Drugs, Costs, Medical treatment, Chronic diseases
Uwagi
summ.
Kraj/Region
Polska
Poland
Abstrakt
Real-World Evidence (RWE) provides insights into patient outcomes reflecting current practices under existing healthcare system conditions. Longitudinal patient data are a source of information that can be used to track treatments for anonymised individual patients over time. Arterial hypertension is one of the most common chronic diseases in Poland, leading to serious complications, especially if undiagnosed and not properly controlled. Fixed-dose combinations of antihypertensive drugs become more and more popular in the treatment of hypertension. The objective of this study was to analyze real-life treatment patterns and medication costs in patients with hypertension treated with the most popular ACEI in Poland - ramipril, in monotherapy, loose and fixed combinations. This analysis was based on the longitudinal prescription database (IMS "LRx") of individual, anonymized patients structured by product, prescribing doctor specialty and patient age group and sex, sourced from dispensing transactions of 3367 chain and non-chain pharmacies, in the Polish open-care market. The period of analysis covers 20 months (January 2014 - August 2015). It is based on 1 488 053 patients and 9 023 582 prescriptions. Cost calculations were performed from payer's and patient's perspectives(original abstract)
Pełny tekst
Pokaż
Bibliografia
Pokaż
  1. Rawlins M, "The Testimono", 2008
  2. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD, Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report, Value Health, 2007 Sep-Oct; 10(5): 326-38
  3. Wierzbicka N, Jahnc-Rozyk K, The evolving landscape for Real World Evidence in Poland: physicians' perspective, JHPOR.2015.1.3: 15-33; DOI: 10.7365
  4. ​Available from: www.aotm.gov.pl cited 24.12.2015
  5. Szkultecka-Dębek M, Drozd M, Real world data guidelines - current status review, JHPOR, 2015, 1, 10-14 / JHPOR.2015.1.2; DOI: 10.7365
  6. Willke RJ, Mullins CD, "Ten commandments" for conducting comparative effectiveness research using "real-world data". Supplement to Journal of Managed Care Pharmacy JMCP, November/December 2011, Vol. 17, No. 9-a
  7. Roche N, Reddel H, Martin R, Brusselle G, Papi A, Thomas M, Postma D, Thomas V, Rand C, Chisholm A, Price D, Respiratory Effectiveness Group: Quality standards for real-world research. Focus on observational database studies of comparative effectiveness, Ann. Am. Thorac. Soc. 2014 Feb; 11 Suppl 2: S99-104; doi: 10.1513/ AnnalsATS.201309-300RM
  8. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies, BMJ, 2007 Oct 20, 335(7624), 806-808; doi: 10.1136/ bmj.39335.541782.AD
  9. Bandosz P. et al., Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study, BMJ, 2012;344:d8136 doi: http://dx.doi.org/10.1136/bmj.d8136
  10. Grodzicki T. et al., Zasady postępowania w nadciśnieniu tętniczym: Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego oraz Kolegium Lekarzy Rodzinnych w Polsce Nadciśnienie Tętnicze, 2008, Vol. 12, No. 5: 317-342
  11. Keiser E. et al., A database analysis to evaluate the risk of cardiovascular events in hypertensive patients being treated with either the single pill combination of valsartan and amlodipine or the respective free combination, Journal of Hypertension, June, 2011, vol. 29
  12. Mishchenko O, Iakovlieva L, Adonkina V, Pharmacoeconomic evaluation of fixed-dose triple combination for antihypertensive therapy in Ukraine, JHPOR, 2014, 1, 66-75, DOI: 10.7365/JHPOR.2014.5.8
  13. Filipiak K et al., Ramipril and amlodipine - new fixed-dose combination in antihypertensive treatment, Nadciśnienie Tętnicze, 2012, Vol. 16, No. 2: 105-119
  14. Widecka K. et al., Clinical effectiveness of a fixed-dose combination therapy with ramipril plus felodipine ER compared to monotherapy with ramipril or felodipine ER or to a fixed-dose combination therapy with verapamil SR and trandolapril or amlodipine and valsartan in treatment of primary hypertension - systematic review, Nadciśnienie Tętnicze, 2011, Vol 15, No. 1: 13-20
  15. Hermanowski T, Jaworski R, Czech M, Pachocki R, Ocena kosztów i efektów leczenia hipotensyjnego przy użyciu dwóch różnych inhibitorów konwertazy angiotensyny: peryndoprylu i enalaprylu, Farmakoekonomika 4/2001; 2-12
  16. Hermanowski T, Borowiec Ł, Faluta T., How to optimize public spending on antihypertensive treatment in Poland - an example of rationalization analysis, JHPOR, 2014, 2, 78-87 DOI: 10.7365/JHPOR.2013.4.9
Cytowane przez
Pokaż
ISSN
2299-1247
Język
eng
URI / DOI
http://dx.doi.org/10.7365/JHPOR.2015.2.4
Udostępnij na Facebooku Udostępnij na Twitterze Udostępnij na Google+ Udostępnij na Pinterest Udostępnij na LinkedIn Wyślij znajomemu